Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Brain : a journal of neurology

• Publication date

  2009-10-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/brain/awp239PMID 19805493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The endocannabinoid system is modulated in response to spinal cord injury in rats.

  2009cited by this paper
• Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

  2009cited by this paper
• Endocannabinoid-mediated neuron-astrocyte communication

  2009cited by this paper
• A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

  2008cited by this paper
• Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis

  2008cited by this paper
• Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

  2008cited by this paper
• NMDA receptors in clinical neurology: excitatory times ahead.

  2008cited by this paper
• CB2 receptor‐mediated migration of immune cells: it can go either way

  2008cited by this paper
• The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.

  2008influential reference
• Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration.

  2008cited by this paper
• Mechanisms of neurodegeneration in Huntington’s disease

  2008cited by this paper
• Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes

  2008cited by this paper
• Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis

  2007cited by this paper
• Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

  2007cited by this paper
• Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

  2007influential reference
• Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

  2007cited by this paper
• The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.

  2007cited by this paper
• Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease

  2007cited by this paper
• Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

  2007cited by this paper
• Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

  2007influential reference
• The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

  2007cited by this paper
• Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.

  2007cited by this paper
• Essential protective roles of reactive astrocytes in traumatic brain injury.

  2006cited by this paper
• The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells.

  2006cited by this paper
• The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

  2006cited by this paper
• The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells

  2006cited by this paper
• Cannabinoid receptors as therapeutic targets.

  2006cited by this paper
• The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.

  2006cited by this paper
• Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury

  2006cited by this paper
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

  2005cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

  2005cited by this paper
• Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli

  2005cited by this paper
• Microglial activation in presymptomatic Huntington's disease gene carriers.

  2005cited by this paper
• Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

  2005cited by this paper
• Cleavage pattern and emerging asymmetry of the mouse embryo

  2005cited by this paper
• Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

  2004cited by this paper
• Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease

  2004cited by this paper
• Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

  2003cited by this paper
• Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease

  2003cited by this paper
• Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

  2003cited by this paper
• Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.

  2002cited by this paper
• Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain

  2001cited by this paper
• Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

  2000cited by this paper
• Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

  2000cited by this paper
• Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.

  2000influential reference
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000influential reference
• HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

  1999influential reference
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996cited by this paper
• Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus

  1994cited by this paper
• The FASEB Journal • FJ Express Full-Length Article Non-psychoactive CB 2 cannabinoid agonists stimulate neural progenitor proliferation

  year unknowncited by this paper

• Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets.

  2026cites this paper
• Neuroglial Function and Hormonal Modulation in Neurodegenerative Diseases: The Influence of Sex Hormones

  2026cites this paper
• Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.

  2025cites this paper
• Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS

  2025cites this paper
• Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation

  2025cites this paper
• Cannabinoid Receptor 2 Agonism Demonstrates Therapeutic Potential in Experimental Models of Relevance to Diabetic Retinopathy.

  2025cites this paper
• Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases.

  2025cites this paper
• Canonical Cannabinoid Receptors.

  2025cites this paper
• Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington’s disease models

  2025cites this paper
• Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders

  2025cites this paper
• Phytocanabinoids and synthetic cannabinoids: from recreational consumption to potential therapeutic use – a review

  2025cites this paper
• Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease

  2025cites this paper
• Cannabinoid Ligand‐Mediated Glycogen Depletion in Astrocytes Is Associated With Increased Intracellular Calcium, Energy Metabolism, and Membrane Dynamics

  2025cites this paper
• Ageing, Neurodegeneration and the Endocannabinoid System.

  2025cites this paper
• Emerging roles of microglia and neuroinflammation in Huntington's disease: From pathophysiology to clinical trials

  2025cites this paper
• Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma.

  2025cites this paper
• Inflammaging and Immunosenescence in the Post‐COVID Era: Small Molecules, Big Challenges

  2024cites this paper
• Acute Effects of Monoacylglycerol Lipase Inhibitor ABX1431 on Neuronal Hyperexcitability, Nociception, Locomotion, and the Endocannabinoid System in HIV-1 Tat Male Mice

  2024cites this paper
• Genetic Tools in Rodents to Study Cannabinoid Functions.

  2024cites this paper
• Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases

  2024cites this paper
• Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer’s disease mice by controlling astrocyte activation

  2024cites this paper
• Cannabinoid type 2 receptor deficiency leads to Aβ-induced cognitive impairment through promoting microglial sensitivity to Aβ in the prefrontal cortex in mice

  2024cites this paper
• Interactions Between the Ubiquitin–Proteasome System, Nrf2, and the Cannabinoidome as Protective Strategies to Combat Neurodegeneration: Review on Experimental Evidence

  2024cites this paper
• Inflammation in Metal-Induced Neurological Disorders and Neurodegenerative Diseases

  2024cites this paper
• Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders

  2024cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

  2024cites this paper
• Associations of inflammatory cytokines and cortisol with nonmotor features of Huntington's disease

  2024cites this paper
• Microglial Dyshomeostasis: A Common Substrate in Neurodevelopmental and Neurodegenerative Diseases

  2024influential citation
• Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation

  2024influential citation
• Inflammation and Huntington’s disease – a neglected therapeutic target?

  2024cites this paper
• Advancement of Research Progress on Synthesis Mechanism of Cannabidiol (CBD)

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro

  2024cites this paper
• Fueling neurodegeneration: metabolic insights into microglia functions

  2024cites this paper
• Receptors on Microglia.

  2024cites this paper
• Exploring the versatile roles of the endocannabinoid system and phytocannabinoids in modulating bacterial infections

  2024cites this paper
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity

  2023cites this paper
• Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease.

  2023cites this paper
• The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington’s Disease

  2023cites this paper
• Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

  2023cites this paper
• CB2 receptor in the CNS: from immune and neuronal modulation to behavior.

  2023cites this paper
• Astrocytic Neuroimmunological Roles Interacting with Microglial Cells in Neurodegenerative Diseases

  2023cites this paper
• The Endocannabinoid System as a Potential Therapeutic Target for HIV-1-Associated Neurocognitive Disorder

  2023cites this paper
• Spinal cannabinoid receptor 2 activation alleviates neuropathic pain by regulating microglia and suppressing P2X7 receptor

  2023cites this paper
• Amendment of Altered Immune Response by Curcumin in Drosophila Model of Huntington’s Disease

  2023cites this paper
• Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions

  2023cites this paper
• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease

  2023cites this paper
• Long-Term Treatment with Cannabidiol-Enriched Cannabis Extract Induces Synaptic Changes in the Adolescent Rat Hippocampus

  2023cites this paper
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy

  2023cites this paper
• Neuroinflammation: A Modifiable Pathway Linking Obesity, Alzheimer's disease, and Depression.

  2023cites this paper
• Associations of Blood Inflammatory Cytokines and Hair Cortisol with Depression Symptoms and Cognitive Functioning in Huntington's Disease

  2023cites this paper
• Interplay between the Glymphatic System and the Endocannabinoid System: Implications for Brain Health and Disease

  2023cites this paper
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders

  2022cites this paper
• Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics

  2022cites this paper
• Impact of the Cannabinoid System in Alzheimer's Disease

  2022cites this paper
• Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential.

  2022cites this paper
• The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review

  2022cites this paper
• Regulation of Expression of Cannabinoid CB2 and Serotonin 5HT1A Receptor Complexes by Cannabinoids in Animal Models of Hypoxia and in Oxygen/Glucose-Deprived Neurons

  2022cites this paper
• The Influence of CB2-Receptor Ligands on the Memory-Related Responses in Connection with Cholinergic Pathways in Mice in the Passive Avoidance Test

  2022cites this paper
• The microglial endocannabinoid system is similarly regulated by lipopolysaccharide and interferon gamma.

  2022cites this paper
• INVOLVEMENT OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY AND THERAPEUTICS OF MOVEMENT DISORDERS

  2022cites this paper
• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential

  2022cites this paper
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders

  2022cites this paper
• Probiotic Bifidobacterium breve MCC1274 Mitigates Alzheimer’s Disease-Related Pathologies in Wild-Type Mice

  2022cites this paper
• Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  2022cites this paper
• Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  2022cites this paper
• Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET.

  2022cites this paper
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease

  2022cites this paper
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  2022influential citation
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation

  2022cites this paper
• Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease

  2022cites this paper
• Class A and C GPCR Dimers in Neurodegenerative Diseases

  2022cites this paper
• Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy

  2022cites this paper
• Parkinson's Disease related alterations in cannabinoid transmission.

  2021cites this paper
• Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  2021cites this paper
• PET Imaging of Neuroinflammation

  2021cites this paper
• Glia: A major player in glutamate–GABA dysregulation‐mediated neurodegeneration

  2021cites this paper
• The endocannabinoid system as a target for the treatment of neurological disorders

  2021cites this paper
• Hippocampal Cb2 receptors: an untold story

  2021cites this paper
• Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease.

  2021cites this paper
• Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

  2021influential citation
• Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice

  2021cites this paper
• Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System

  2021cites this paper
• Δ9‐Tetrahydrocannabinol promotes functional remyelination in the mouse brain

  2021cites this paper
• A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid.

  2021cites this paper
• Inactivation of the CB 2 receptor accelerated the neuropathological deterioration in TDP- 43 transgenic mice, a model of amyotrophic lateral sclerosis

  2021cites this paper
• The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation

  2021cites this paper
• Cannabinoid receptors distribution in mouse cortical plasma membrane compartments

  2021cites this paper
• Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

  2021cites this paper
• Effect of Cannabinoid 2 Receptor Modulation on the Peripheral Immune Response in Central Nervous System Injury-Induced Immunodeficiency Syndrome

  2021cites this paper
• Untapped endocannabinoid pharmacological targets: pipe dream or pipeline?

  2021cites this paper
• Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases.

  2021cites this paper
• Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain

  2021cites this paper
• The cannabinoid system and microglia in health and disease.

  2021cites this paper
• Cannabidiol regulates CB1‐pSTAT3 signaling for neurite outgrowth, prolongs lifespan, and improves health span in Caenorhabditis elegans of Aβ pathology models

  2021cites this paper
• Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

  2021cites this paper
• Mini-review: The therapeutic role of cannabinoids in neuroHIV

  2021cites this paper
• Human Huntington’s disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species

  2021cites this paper
• The CB2 cannabinoid receptor as a therapeutic target in the central nervous system

  2021cites this paper